Fresenius Group Overview

Results Center

To archive

Q1/20 Results

Solid start to 2020 – Fresenius proves its resilience in light of significant COVID-19 effects
  • Fresenius Medical Care with strong sales growth in Q1

  • Fresenius Kabi with expected dip in China partially offset by spike in demand for drugs and devices for COVID-19 patients in Europe and the US

  • Helios Germany supported by law to ease financial burden on hospitals

  • Helios Spain’s significant contribution to combat COVID-19 faces reimbursement uncertainties

  • Fresenius Vamed with solid Q1, however already marked by COVID-19 related post-acute patient losses and project delays

  • Original guidance for 2020 excluding any effects of the COVID-19 pandemic maintained; Guidance update to include COVID-19 effects expected with Q2/20 financial results

  • Group financial position remains strong

Selected Key Figures Q1/20

Key figures Q1 2020

1 Figures are not comparable to guidance as FY/20 guidance does not include any effects from Covid 19 pandemic.

2 In constant currency

3 Before special items

4 Net income attributable to shareholders of Fresenius SE & Co. KGaA